Piper Jaffray Companies reissued their hold rating on shares of Allergan PLC. (NYSE:AGN) in a research report sent to investors on Friday morning. Piper Jaffray Companies currently has a $231.00 price objective on the stock.

Other equities analysts also recently issued research reports about the stock. UBS AG reiterated a buy rating and issued a $275.00 price target on shares of Allergan PLC. in a report on Monday, May 15th. Royal Bank Of Canada set a $284.00 price target on shares of Allergan PLC. and gave the company a buy rating in a report on Monday, June 12th. Mizuho cut their price target on shares of Allergan PLC. from $275.00 to $267.00 and set a buy rating for the company in a report on Friday, June 9th. Cowen and Company set a $400.00 price target on shares of Allergan PLC. and gave the company a buy rating in a report on Thursday, June 8th. Finally, Deutsche Bank AG increased their price target on shares of Allergan PLC. from $262.00 to $265.00 and gave the company a buy rating in a report on Tuesday, March 28th. Seven research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $273.15.

Shares of Allergan PLC. (NYSE AGN) traded up 0.68% during mid-day trading on Friday, hitting $247.53. 1,438,443 shares of the stock traded hands. The firm has a market cap of $83.14 billion, a price-to-earnings ratio of 7.71 and a beta of 1.16. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $261.27. The firm’s 50 day moving average price is $231.35 and its 200 day moving average price is $230.10.

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings results on Tuesday, May 9th. The company reported $3.35 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.32 by $0.03. The business had revenue of $3.57 billion during the quarter, compared to the consensus estimate of $3.53 billion. Allergan PLC. had a net margin of 82.42% and a return on equity of 7.29%. The business’s revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the firm posted $3.04 EPS. On average, equities research analysts predict that Allergan PLC. will post $16.09 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Allergan PLC. (NYSE:AGN) Given “Hold” Rating at Piper Jaffray Companies” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/07/17/allergan-plc-nyseagn-given-hold-rating-at-piper-jaffray-companies.html.

In related news, Director Nesli Basgoz sold 1,889 shares of the firm’s stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.36% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Cacti Asset Management LLC raised its stake in Allergan PLC. by 1.3% in the first quarter. Cacti Asset Management LLC now owns 196,920 shares of the company’s stock worth $47,221,000 after buying an additional 2,600 shares in the last quarter. Beacon Financial Group purchased a new stake in Allergan PLC. during the first quarter worth about $325,000. Kentucky Retirement Systems Insurance Trust Fund purchased a new stake in Allergan PLC. during the fourth quarter worth about $2,550,000. Kentucky Retirement Systems purchased a new stake in Allergan PLC. during the fourth quarter worth about $5,716,000. Finally, Auxier Asset Management raised its stake in Allergan PLC. by 16.1% in the fourth quarter. Auxier Asset Management now owns 7,840 shares of the company’s stock worth $1,646,000 after buying an additional 1,090 shares in the last quarter. Hedge funds and other institutional investors own 84.53% of the company’s stock.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.